Urigen Pharmaceuticals fka URGP

[Apophis]

Summary of our Patents and Patent Applications for URG 101 Product Development:







?


We have licensed a series of patents and patent applications entitled "Novel Interstitial Therapy for Immediate Symptom Relief and Chronic Therapy in Interstitial Cystitis" from the University of California, San Diego. These patents and patent applications claim treatment formulations and methods for reducing the symptoms of urinary frequency, urgency, and/or pelvic pain, including interstitial cystitis. These patents and patent applications include: (a) United States Patent No. 7,414,039; (b) Australian Patent Application Serial No. 2005209322, Sealed (granted); (c) European Patent Application No. 05712839.9; (d) Canadian Patent Application 2554489; and (e) United States Patent Application Serial No. 12/188,134.








?


We have filed PCT Application Serial No. PCT/US2006/019745 entitled "Kits and Improved Compositions for Treating Lower Urinary Tract Disorders," which is directed to superior buffered formulations and kits for treating lower urinary tract symptoms and disorders, including interstitial cystitis. This PCT application is the basis for a number of national and regional stage applications, including: (a) United States Patent Application Serial Nos. 11/813,941and 13/442,101; (b) Canadian Patent Application Serial No. 2,637,141; (c) European Patent Application Serial No. 06718460.6; (d) Korean Patent Application Serial No. 10-2007-7018672; and (e) Japanese Patent Application Serial No. 2007551439.